<!DOCTYPE html>
<html lang="zh-CN">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=5.0">
    <title>ç§‘ç ”æ—¥æŠ¥ - 2025-12-27</title>
    <style>
        * {
            margin: 0;
            padding: 0;
            box-sizing: border-box;
        }

        body {
            font-family: -apple-system, BlinkMacSystemFont, "Segoe UI", Roboto, "Helvetica Neue", Arial, "Noto Sans", sans-serif, "Apple Color Emoji", "Segoe UI Emoji";
            line-height: 1.8;
            color: #2c3e50;
            background: linear-gradient(135deg, #f5f7fa 0%, #c3cfe2 100%);
            padding: 15px;
            font-size: 16px;
        }

        .container {
            max-width: 900px;
            margin: 0 auto;
            background: white;
            padding: 35px;
            border-radius: 16px;
            box-shadow: 0 10px 40px rgba(0,0,0,0.1);
        }

        /* æ ‡é¢˜ä¼˜åŒ– */
        h1 {
            color: #1a202c;
            font-size: 2em;
            border-bottom: 4px solid #667eea;
            padding-bottom: 15px;
            margin-bottom: 25px;
            font-weight: 700;
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            -webkit-background-clip: text;
            -webkit-text-fill-color: transparent;
            background-clip: text;
        }

        h2 {
            color: #2d3748;
            font-size: 1.5em;
            margin-top: 40px;
            margin-bottom: 20px;
            padding-left: 15px;
            border-left: 5px solid #667eea;
            font-weight: 600;
        }

        h3 {
            color: #4a5568;
            font-size: 1.25em;
            margin-top: 28px;
            margin-bottom: 14px;
            font-weight: 600;
        }

        /* åˆ†ç±»æµè§ˆæŠ˜å åŠŸèƒ½ */
        details {
            margin: 20px 0;
            border-radius: 8px;
            overflow: hidden;
        }

        details summary {
            cursor: pointer;
            padding: 15px 20px;
            background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%);
            color: #2d3748;
            font-size: 1.25em;
            font-weight: 600;
            text-align: right;
            direction: rtl;
            border-right: 5px solid #667eea;
            transition: all 0.3s ease;
            list-style: none;
            user-select: none;
        }

        details summary * {
            direction: ltr;
        }

        details summary::-webkit-details-marker {
            display: none;
        }

        details summary::before {
            content: 'â–¶';
            display: inline-block;
            margin-left: 10px;
            transition: transform 0.3s ease;
            font-size: 0.8em;
        }

        details[open] summary::before {
            transform: rotate(90deg);
        }

        details summary:hover {
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            color: white;
            box-shadow: 0 4px 12px rgba(102, 126, 234, 0.3);
        }

        details[open] summary {
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            color: white;
            border-right-color: white;
        }

        details .details-content {
            padding: 20px;
            background: white;
            border: 1px solid #e9ecef;
            border-top: none;
        }

        h4 {
            color: #718096;
            font-size: 1.1em;
            margin-top: 22px;
            margin-bottom: 12px;
            font-weight: 600;
        }

        p {
            margin-bottom: 16px;
            line-height: 1.8;
        }

        blockquote {
            background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%);
            border-left: 4px solid #667eea;
            padding: 18px 22px;
            margin: 22px 0;
            border-radius: 8px;
            color: #4a5568;
            font-size: 0.95em;
            box-shadow: 0 2px 8px rgba(0,0,0,0.05);
        }

        blockquote p {
            margin-bottom: 8px;
        }

        blockquote p:last-child {
            margin-bottom: 0;
        }

        blockquote em {
            font-style: normal;
            color: #718096;
            font-size: 0.9em;
        }

        blockquote a {
            color: #667eea;
            font-weight: 500;
            border-bottom: 1px solid rgba(102, 126, 234, 0.3);
        }

        blockquote a:hover {
            color: #764ba2;
            border-bottom-color: #764ba2;
        }

        /* é¡¶éƒ¨ç½²åï¼ˆå±…å³ï¼‰ */
        .powered-by-top {
            text-align: right;
            font-size: 0.85em;
            color: #718096;
            font-style: italic;
            margin: 12px 0;
            padding-right: 5px;
        }

        .powered-by-top a {
            color: #667eea;
            font-weight: 500;
            border-bottom: 1px solid rgba(102, 126, 234, 0.3);
        }

        .powered-by-top a:hover {
            color: #764ba2;
            border-bottom-color: #764ba2;
        }

        /* AI æ€»ç»“åŒºåŸŸä¼˜åŒ– */
        .ai-summary {
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            color: white;
            padding: 28px;
            border-radius: 16px;
            margin: 30px 0;
            box-shadow: 0 12px 35px rgba(102, 126, 234, 0.35);
            position: relative;
            overflow: hidden;
        }

        .ai-summary::before {
            content: '';
            position: absolute;
            top: -50%;
            right: -50%;
            width: 200%;
            height: 200%;
            background: radial-gradient(circle, rgba(255,255,255,0.1) 0%, transparent 70%);
            pointer-events: none;
        }

        .ai-summary h2 {
            color: white;
            border-left: none;
            border-right: none;
            margin-top: 0;
            margin-bottom: 18px;
            padding-left: 15px;
            padding-right: 0;
            text-align: left;
            direction: ltr;
        }

        .ai-summary h3 {
            color: #f0f0f0;
            margin-top: 18px;
            border-right: 3px solid rgba(255,255,255,0.5);
            padding-right: 12px;
            padding-left: 0;
            text-align: right;
            direction: rtl;
        }

        .ai-summary h3 * {
            direction: ltr;
        }

        .ai-summary blockquote {
            background: rgba(255,255,255,0.15);
            border-left-color: white;
            color: white;
            backdrop-filter: blur(10px);
        }

        .ai-summary p {
            color: white;
        }

        .ai-summary strong {
            color: #fff;
            font-weight: 600;
        }

        ul, ol {
            margin-left: 28px;
            margin-bottom: 18px;
        }

        li {
            margin-bottom: 12px;
            line-height: 1.8;
        }

        /* é“¾æ¥ä¼˜åŒ– */
        a {
            color: #667eea;
            text-decoration: none;
            border-bottom: 1px solid transparent;
            transition: all 0.3s ease;
            font-weight: 500;
        }

        a:hover {
            border-bottom-color: #667eea;
            color: #764ba2;
        }

        /* è¡¨æ ¼ä¼˜åŒ– */
        table {
            width: 100%;
            border-collapse: collapse;
            margin: 20px 0;
            box-shadow: 0 2px 12px rgba(0,0,0,0.08);
            border-radius: 10px;
            overflow: hidden;
        }

        th, td {
            border: 1px solid #e2e8f0;
            padding: 14px 18px;
            text-align: left;
        }

        th {
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            color: white;
            font-weight: 600;
            font-size: 0.95em;
        }

        tr:nth-child(even) {
            background: #f8f9fa;
        }

        tr:hover {
            background: #e9ecef;
            transition: background 0.3s ease;
        }

        /* å…³é”®è¯ç»Ÿè®¡è¡¨æ ¼ç‰¹æ®Šæ ·å¼ï¼ˆæ›´ç´§å‡‘ï¼‰ */
        .keywords-table {
            font-size: 0.9em;
            max-width: 600px;
        }

        .keywords-table th,
        .keywords-table td {
            padding: 10px 14px;
        }

        .keywords-table th {
            font-size: 0.9em;
        }

        hr {
            border: none;
            border-top: 2px solid #e2e8f0;
            margin: 40px 0;
        }

        strong {
            color: #2d3748;
            font-weight: 600;
        }

        code {
            background: #f1f5f9;
            padding: 3px 8px;
            border-radius: 5px;
            font-family: "SF Mono", Monaco, Consolas, "Courier New", monospace;
            font-size: 0.9em;
            color: #e53e3e;
        }

        /* ç¾åŒ–æ»šåŠ¨æ¡ */
        ::-webkit-scrollbar {
            width: 8px;
            height: 8px;
        }

        ::-webkit-scrollbar-track {
            background: #f1f1f1;
            border-radius: 4px;
        }

        ::-webkit-scrollbar-thumb {
            background: #667eea;
            border-radius: 4px;
        }

        ::-webkit-scrollbar-thumb:hover {
            background: #764ba2;
        }

        /* ç§»åŠ¨ç«¯ä¼˜åŒ– */
        @media (max-width: 768px) {
            body {
                padding: 8px;
                font-size: 15px;
            }

            .container {
                padding: 22px 18px;
                border-radius: 12px;
            }

            h1 {
                font-size: 1.6em;
                padding-bottom: 12px;
                margin-bottom: 20px;
            }

            h2 {
                font-size: 1.3em;
                margin-top: 30px;
                padding-left: 12px;
            }

            h3 {
                font-size: 1.15em;
            }

            h4 {
                font-size: 1.05em;
            }

            blockquote {
                padding: 14px 16px;
                margin: 18px 0;
            }

            .ai-summary {
                padding: 20px;
                margin: 22px 0;
            }

            .ai-summary-header {
                flex-direction: column;
                align-items: flex-start;
            }

            .powered-by {
                margin-left: 0;
                margin-top: 8px;
            }

            table {
                font-size: 0.85em;
            }

            th, td {
                padding: 10px 12px;
            }

            .keywords-table {
                font-size: 0.8em;
            }

            .keywords-table th,
            .keywords-table td {
                padding: 8px 10px;
            }

            ul, ol {
                margin-left: 22px;
            }
        }

        /* è¶…å°å±å¹• */
        @media (max-width: 480px) {
            body {
                font-size: 14px;
                padding: 5px;
            }

            .container {
                padding: 18px 14px;
            }

            h1 {
                font-size: 1.4em;
            }

            h2 {
                font-size: 1.2em;
            }

            .ai-summary {
                padding: 16px;
            }

            .powered-by {
                font-size: 0.7em;
            }
        }

        /* å¹³æ»‘æ»šåŠ¨ */
        html {
            scroll-behavior: smooth;
        }

        /* æé«˜å¯ç‚¹å‡»åŒºåŸŸ */
        @media (pointer: coarse) {
            a {
                padding: 4px 0;
                display: inline-block;
            }
        }

        /* æ‰“å°ä¼˜åŒ– */
        @media print {
            body {
                background: white;
                padding: 0;
            }

            .container {
                box-shadow: none;
                max-width: 100%;
            }

            .ai-summary {
                background: #f5f5f5;
                color: black;
                box-shadow: none;
            }

            .ai-summary h2,
            .ai-summary h3,
            .ai-summary p,
            .ai-summary strong {
                color: black;
            }
        }
    </style>
</head>
<body>
    <div class="container">
        <h1>ğŸ“… Daily Report - 2025-12-27</h1>
<blockquote>
<p>ä»Šæ—¥ç­›é€‰å‡º <strong>17</strong> æ¡å†…å®¹ï¼Œæ¥è‡ª <strong>1</strong> ä¸ªæ¥æº</p>
</blockquote>
<div class="powered-by-top">Powered by <a href="https://kyplus.de" target="_blank" rel="noopener noreferrer">ç§‘ç ”æ™®æ‹‰æ–¯</a> & <a href="https://claude.ai" target="_blank" rel="noopener noreferrer">Claude</a></div>

<hr />
<div class="ai-summary">
                <h2>ğŸ¤– ä»Šæ—¥AIæ™ºèƒ½æ€»ç»“</h2>
                <h3>ğŸ§¬ æ•°æ®å‰æ²¿</h3>
<blockquote>
<p><strong>ä»Šæ—¥ç„¦ç‚¹</strong>ï¼š<br />
ç©ºé—´è½¬å½•ç»„å­¦æ­ç¤ºäººå‚çš‚è‹·Rb1ä¸å°æª—ç¢±ååŒè°ƒæ§GDF15/HAMPä¿¡å·é€šè·¯ï¼Œä¸º2å‹ç³–å°¿ç—…æ²»ç–—æä¾›æ–°æ€è·¯ã€‚</p>
</blockquote>
<p><strong>ä¸»è¦æ–¹å‘</strong>ï¼š<br />
- è‚¿ç˜¤å¾®ç¯å¢ƒé‡å¡‘ä¸å…ç–«æ²»ç–—æŠµæŠ—æœºåˆ¶ï¼ˆå¦‚AXLæŠ—ä½“ã€è„‚è‚ªé…¸ä»£è°¢é©±åŠ¨ç™Œç»†èƒè½¬ç§»ã€åŒ–ç–—è¯±å¯¼Kupfferç»†èƒåˆ†åŒ–ï¼‰ã€‚<br />
- ç»†èƒå¼‚è´¨æ€§è§£æä¸ç–¾ç—…å‘ç”Ÿå‘å±•ï¼ˆå¦‚è‚¾ä¸Šè…ºçš®è´¨ç™Œã€åŸå§‹é€ è¡€ï¼‰ã€‚<br />
- åŸºå› è°ƒæ§ä¸ç»†èƒåŠŸèƒ½ï¼ˆå¦‚æŸ“è‰²è´¨ç»„è£…å› å­1åœ¨åŸºå› æ²‰é»˜ä¸­çš„ä½œç”¨ã€AUF1è°ƒæ§å…ç–«åŸºå› çš„è½¬å½•ä¸å‰ªæ¥ï¼‰ã€‚</p>
<p><strong>æŠ€æœ¯äº®ç‚¹</strong>ï¼š<br />
- ç©ºé—´è½¬å½•ç»„å­¦åˆ†æã€‚<br />
- å•ç»†èƒå¤šç»„å­¦åˆ†æã€‚</p>
            </div><h2>ğŸ“š åˆ†ç±»æµè§ˆ</h2>
<details>
<summary style="text-align: right; direction: rtl; padding: 10px 15px; background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%); border-right: 4px solid #667eea; font-weight: 600; cursor: pointer; margin: 15px 0; border-radius: 6px;">ğŸ§¬ æ•°æ®å‰æ²¿ (17æ¡)</summary>
<div class="details-content">
<h4>è¯¦ç»†å†…å®¹ï¼ˆå‰10æ¡ï¼‰</h4>
<p><strong>1.</strong> â­ <strong>GSE314707 åˆ©ç”¨è†œè¿‘ç«¯ AXL æŠ—ä½“é‡ç¼–ç¨‹è‚¿ç˜¤å¾®ç¯å¢ƒä»¥å…‹æœå…ç–«æ£€æŸ¥ç‚¹é˜»æ–­è€è¯æ€§</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼štumorã€immuneã€tumor microenvironmentã€antibodyã€resistance<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Zuming Yang ; Shuai CaoSeries Type : Expression profiling by high throughput sequencingOrganism : Mus musculusImmune-cold tumors failed to respond to immunotherapy due to insufficient lymphocytes infiltration within tumor tissue. How to increase the objective response rate is an urgent challenge. Here, we report the development of a monoclonal antibody (6C5) that specifically targets the membrane-proximal epitope of receptor tyrosine kinase AXL, which modulates the anti-tumor immunity. Unlike traditional membrane-distal AXL antibodies, 6C5 significantly enhanced innate immune sensing by promoting macrophage-mediated antigen uptake and type I interferon production via the MyD88 pathway. This reshaped the tumor microenvironment , further boosting CD8+ T cell infiltration and effector function. However, AXL antibody treatment concurrently induced a suppressive subset of PD-1hiFoxp3-CD4+ T cell, attenuating antitumor responses. The combination of AXL Ab with dual immune checkpoint blockade (anti-PD-1 plus anti-CTLA-4) or PD-1-targeted IL-2 fusion protein therapy mitigated this immunosuppression, achieving potent tumor regression and durable immune memory. Our findings demonstrate that membrane-proximal AXL targeting antibody effectively converts immune-cold tumor microenvironment, overcoming resistance to both conventional and next-generation immune checkpoint inhibitors.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE314707" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>2.</strong> â­ <strong>GSE285791 äººå‚çš‚è‹·Rb1å’Œé»„è¿ç´ é€šè¿‡GDF15/HAMPä¿¡å·é€šè·¯åœ¨è‚å°å¶ä¸­å¯¹2å‹ç³–å°¿ç—…å‘æŒ¥ååŒä¿æŠ¤ä½œç”¨ï¼šç©ºé—´è½¬å½•ç»„å­¦åˆ†æçš„å¯ç¤º</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šspatialã€spatial transcriptomicsã€transcriptomicsã€pathway<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Rongfang Guo ; Shuying Zhang ; Anyao Li ; Ping Zhang ; Xin Peng ; Xiaoyan Lu ; Xiaohui FanSeries Type : OtherOrganism : Mus musculusType 2 diabetes mellitus (T2DM) is a significant public health issue with high mortality and morbidity. Ginsenoside Rb1 and berberine, the main bioactive compounds of Panax ginseng and Coptis chinensis, respectively, are known for their hypoglycemic effects. Nevertheless, the synergistic effects and underlying mechanism of ginsenoside Rb1 and berberine on T2DM remain unclear. In this study, we utilized a leptin receptor- deficient (db/db) mouse model to investigate the protective effects of their combination treatment. Our findings demonstrated that the combined use of ginsenoside Rb1 and berberine at a 1:4 ratio had more pronounced effects than the first-line anti-diabetic drug metformin on reducing the weight ratio of white adipose tissue, ameliorating insulin resistance, and improving glucose and lipid metabolism. Using spatial transcriptomics, we revealed that metformin treatment improved gluconeogenesis and lipogenesis only in the periportal zone, while the combination treatment induced improvements throughout the liver lobule, with distinct key targets across different zones, thus underscoring a more comprehensive and nuanced modulation of hepatic metabolism. This may be the key reason why this combination therapy demonstrated superior protective effects against T2DM. Additionally, the reversed expression of the key callback gene Hamp and its regulator Gdf15 following the combination therapy across all zones, along with validation experiments, further suggested that the GDF15/HAMP signaling pathway might be a key mechanism underlying the beneficial effects of ginsenoside Rb1 and berberine against T2DM. This study also indicates a path toward innovative drug cocktails for treating T2DM, offering a holistic approach to regulate the entire liver lobule metabolism.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE285791" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>3.</strong> â­ <strong>GSE314457 åŸºè´¨ç»†èƒå¯¹è„‚è‚ªé…¸çš„ä»£è°¢é€‚åº”é©±åŠ¨å£è…”é³çŠ¶ç»†èƒç™Œçš„è½¬ç§» [RNA-Seq]</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šcarcinomaã€metabolicã€RNA-seq<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Yiling Duan ; Yitong Li ; Yufei Wu ; Rui Li ; Xiao Yang ; Hui Zhao ; Zhengjun ShangSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensMetabolic adaptation enables cancer cell survival under nutrient stress, but how stromal cells in tumor microenvironment (TME) withstand similar metabolic change remains elusive. Here, we report that fatty acids (FAs), a nutrient with dual roles in energy provision and lipotoxicity, orchestrate a pro-metastatic adaptation program in cancer-associated fibroblasts (CAFs). In patients with oral squamous cell carcinoma (OSCC), the FA transporter CD36 was upregulated not only in cancer cells but also in myofibroblastic CAFs (myoCAFs), where it correlated with more advanced metastasis stage. Among 5 kinds of FAs enriched in OSCC tissues, palmitic acid (PA) potently activated myoCAFs phenotypes across 2D, 3D, and organoid co-culture models. In vivo, PA promoted lymph node metastasis in orthotopic tumors comprising OSCC cells and CAFs, an effect abolished by CD36 knockdown in CAFs. Mechanistically, PA engaged chromatin occupancy of H3K27ac at multiple genes including IRE1 and TMBIM6, two stress-adaptive regulators. Transcription of IRE1 and TMBIM6 in CAFs was regulated by CCAAT/enhancer-binding protein Î³ (CEBPG) through an enhancer-dependent manner. Disruption of the CEBPGâ€“IRE1/TMBIM6 axis attenuated myoCAFs properties and abrogated PA-driven metastasis. Our results unveil a stromal metabolic checkpoint and establish CEBPG-enhanced stress resilience as a therapeutic target to curtail metastasis.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE314457" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>4.</strong> <strong>GSE252113 é€šè¿‡å•ç»†èƒå¤šç»„å­¦åˆ†æå‰–æè‚¾ä¸Šè…ºçš®è´¨ç™Œçš„è‚¿ç˜¤å†…å’Œè‚¿ç˜¤é—´å¼‚è´¨æ€§</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šcarcinomaã€single-cell<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šSeries Type : OtherOrganism : Homo sapiensThis SuperSeries is composed of the SubSeries listed below.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE252113" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>5.</strong> <strong>GSE252112 é€šè¿‡å•ç»†èƒå¤šç»„å­¦åˆ†æå‰–æè‚¾ä¸Šè…ºçš®è´¨ç™Œçš„è‚¿ç˜¤å†…å’Œè‚¿ç˜¤é—´å¼‚è´¨æ€§[II]</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šcarcinomaã€single-cell<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Xiangyu Pan ; Shengzhuo Liu ; Yu Liu ; Chong ChenSeries Type : OtherOrganism : Homo sapiensAdrenocortical carcinoma (ACC) is a rare but aggressive malignancy originating in the adrenal cortex, characterized by significant intra- and intertumoral heterogeneity. In this study, we employed a combination of whole-genome sequencing, single-cell RNA sequencing, T cell receptor sequencing, spatial transcriptome sequencing, and multiple fluorescent staining to construct a comprehensive multi-omics landscape of ACC. Our findings demonstrated that, although all tumor cells exhibited a "confused cell identity" feature, distinct subpopulations were present in each ACC patient. Among these, the LDLR+ and MKI67+ subpopulations expressed elevated levels of C1A signature genes and established robust communication with endothelial cells through NECTIN-PVR and NOTCH2-JAG pairs, both significantly associated with poor prognosis. Interestingly, the PCDH15+ subpopulations displayed moderate levels of both C1A signature genes and extracellular matrix related genes. On the other hand, the HLA-B+ and subpopulation exhibited the highest levels of antigen-processing related genes, a characteristic not previously reported. The amalgamation of these distinct subpopulations facilitated the stratification of ACC patients into subtypes with varying prognoses. Patients (Group II) dominated by LDLR+ and MKI67+ subpopulations exhibited the worst prognosis, while those (Group III) with a higher proportion of PCDH15+ subpopulation demonstrated the most favorable outcomes. Significantly, patients (Group I) with a higher prevalence of the HLA-B+ subpopulation also showed notably increased LAG3+ memory CD8 T cells, indicating their potential suitability for immunotherapy. Despite responding averagely to conventional treatment, this subgroup was predicted to be responsive to immunotherapy. Notably, one patient from Group I exhibited a positive response to camrelizumab treatment after relapse with mitotane, leading to a successful outcome, while two patients from Group II did not respond favorably. Our study offers insights into the single-cell level heterogeneity of ACC and provides valuable implications for precision treatments for this disease.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE252112" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>6.</strong> <strong>GSE252108 é€šè¿‡å•ç»†èƒå¤šç»„å­¦åˆ†æå‰–æè‚¾ä¸Šè…ºçš®è´¨ç™Œçš„è‚¿ç˜¤å†…å’Œè‚¿ç˜¤é—´å¼‚è´¨æ€§[I]</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šcarcinomaã€single-cell<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Xiangyu Pan ; Shengzhuo Liu ; Yu Liu ; Chong ChenSeries Type : OtherOrganism : Homo sapiensAdrenocortical carcinoma (ACC) is a rare but aggressive malignancy originating in the adrenal cortex, characterized by significant intra- and intertumoral heterogeneity. In this study, we employed a combination of whole-genome sequencing, single-cell RNA sequencing, T cell receptor sequencing, spatial transcriptome sequencing, and multiple fluorescent staining to construct a comprehensive multi-omics landscape of ACC. Our findings demonstrated that, although all tumor cells exhibited a "confused cell identity" feature, distinct subpopulations were present in each ACC patient. Among these, the LDLR+ and MKI67+ subpopulations expressed elevated levels of C1A signature genes and established robust communication with endothelial cells through NECTIN-PVR and NOTCH2-JAG pairs, both significantly associated with poor prognosis. Interestingly, the PCDH15+ subpopulations displayed moderate levels of both C1A signature genes and extracellular matrix related genes. On the other hand, the HLA-B+ and subpopulation exhibited the highest levels of antigen-processing related genes, a characteristic not previously reported. The amalgamation of these distinct subpopulations facilitated the stratification of ACC patients into subtypes with varying prognoses. Patients (Group II) dominated by LDLR+ and MKI67+ subpopulations exhibited the worst prognosis, while those (Group III) with a higher proportion of PCDH15+ subpopulation demonstrated the most favorable outcomes. Significantly, patients (Group I) with a higher prevalence of the HLA-B+ subpopulation also showed notably increased LAG3+ memory CD8 T cells, indicating their potential suitability for immunotherapy. Despite responding averagely to conventional treatment, this subgroup was predicted to be responsive to immunotherapy. Notably, one patient from Group I exhibited a positive response to camrelizumab treatment after relapse with mitotane, leading to a successful outcome, while two patients from Group II did not respond favorably. Our study offers insights into the single-cell level heterogeneity of ACC and provides valuable implications for precision treatments for this disease.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE252108" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>7.</strong> <strong>GSE285991 åŒ–ç–—é€šè¿‡ä¿ƒè¿›è‚è½¬ç§»ç˜¤ä¸­LEPR+åº“æ™®å¼—ç»†èƒåˆ†åŒ–æ¥è§¦å‘å…ç–«é€ƒé€¸</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šimmune<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Xuege Wang ; Qiang PanSeries Type : Genome binding/occupancy profiling by high throughput sequencing ; Expression profiling by high throughput sequencing ; OtherOrganism : Homo sapiens ; Mus musculusThis SuperSeries is composed of the SubSeries listed below.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE285991" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>8.</strong> <strong>GSE314794 é•¿æ˜¥æ–°ç¢±é€šè¿‡ä¸‹è°ƒTssk4å’ŒCcdc159è¯±å¯¼B-ALL PDXå°é¼ æ¨¡å‹ç²¾å­å‘ç”Ÿéšœç¢ï¼šRNA-seqè½¬å½•ç»„åˆ†æ</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šRNA-seq<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Chaoming Zhou ; Meng Fu ; Suyun Chen ; Shengqi Zheng ; Xu CuiSeries Type : Expression profiling by high throughput sequencingOrganism : Mus musculusThis dataset contains RNA sequencing (RNA-seq) data generated from testicular tissues of a B-cell acute lymphoblastic leukemia (B-ALL) patient-derived xenograft (PDX) mouse model treated with vincristine (VCR). The study aimed to elucidate the molecular mechanisms underlying VCR-induced reproductive toxicity. Samples were collected from multiple experimental groups, including normal controls (NC), leukemia-bearing controls (ALL), and VCR-treated groups with varying leukemia infiltration levels. Transcriptomic analysis revealed widespread gene expression perturbations following VCR exposure, with significant downregulation of genes crucial for spermatogenesis and sperm flagellar assembly. This data provides a comprehensive resource for understanding the genetic pathways affected by VCR in the testicular microenvironment.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE314794" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>9.</strong> <strong>GSE314727 VGSC çªå˜å’Œ P450 è¿‡è¡¨è¾¾ä¸æ¸æç”°æ£‰èšœï¼ˆAphis gossypii Gloverï¼‰çš„ Î²-æ°¯æ°°èŠé…¯æŠ—æ€§ç›¸å…³</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šresistance<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Fang Wang ; Shujing Zhang ; Yunfei ZhangSeries Type : Expression profiling by high throughput sequencingOrganism : Aphis gossypiiIdentification and characterization of genes and target-site mutations associated with beta-cypermethrin resistance in Aphis gossypii Glover collected from a Chinese wolfberry (Lycium barbarum L.) field. we collected a beta-cypermethrin resistant A. gossypii strain (HSP) from a Chinese wolf-berry orchard in a major growing area of Ningxia wolfberry (Wuzhong city). Subsequently, to elucidate the potential roles of P450s, CarEs and GSTs in beta-cypermethrin resistance in the A. gossypii strain, we performed synergistic bioassays, as well as enzyme activity assays, to confirm their effects. Further, we carried out a comparative transcriptome anal-ysis to identified the overexpression of detoxification enzyme genes associated with the beta-cypermethrin resistance. According to the transcriptome variations, we also meas-ured the expression levels of the upregulated P450s genes involved in beta-cypermethrin resistance in the A. gossypii resistant strain, using a quantitative real-time PCR assay. Moreover, the potential mutations in VGSC genes and their frequencies were detected to reveal the VGSC genotype of the resistant strain.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE314727" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>10.</strong> <strong>GSE314683 æŸ“è‰²è´¨ç»„è£…å› å­ 1 æ˜¯ç²—ç³™è„‰å­¢èŒæ­£å¸¸åŸºå› æŠ‘åˆ¶å’Œå…¼æ€§å¼‚æŸ“è‰²è´¨å½¢æˆæ‰€å¿…éœ€çš„ [ChIP-seq]</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šChIP-seq<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Eduardo V Torres ; Collin D Link ; Rochelle Yap ; Aileen R Ferraro ; Abigail M Deaven ; Jackie F Pelham ; Zachary A LewisSeries Type : Genome binding/occupancy profiling by high throughput sequencingOrganism : Neurospora crassaFormation of facultative heterochromatin by Polycomb Repressive Complex 2 (PRC2) is a well conserved epigenetic mechanism that functions to control transcriptional dynamics across eukaryotes. PRC2 catalyzes histone H3 lysine 27 tri-methylation (H3K27me3), a histone post-translational modification that helps maintain stable gene repression. Gene repression by PRC2 is important for organismal development and defects in PRC2 function are associated with human ailments, such as Weaver syndrome and various cancers. In this study, we reveal the replication-dependent histone chaperone, Chromatin Assembly Factor 1 (CAF-1), is required for normal facultative heterochromatin formation in model fungus N. crassa. CAF-1 deficiency results in widespread misregulation of gene expression, particularly within facultative heterochromatin domains, which is accompanied by a rearrangement of H3K27me3 patterns. Regional losses of H3K27me3 are associated with reduced levels of ASH-1 catalyzed H3K36 methylation, and gains of histone modifications associated with active transcription. Furthermore, analysis of a double mutant deficient for both CAF-1 and PRC2 activity revealed that these complexes play distinct roles in maintaining gene repression and facultative heterochromatin. Collectively, these results shed light on CAF-1's role in maintaining a repressive chromatin environment.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE314683" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<blockquote>
<p>ğŸ’¡ è¯¥æ¥æºè¿˜æœ‰ 7 æ¡å†…å®¹ï¼Œè¯¦è§ <a href="#æ›´å¤š-æ•°æ®å‰æ²¿">æ–‡æœ«</a></p>
</blockquote>
</div>
</details>

<h2>ğŸ“Š å…³é”®è¯ç»Ÿè®¡</h2>
<table class="keywords-table">
<thead>
<tr>
<th>å…³é”®è¯</th>
<th>å‡ºç°æ¬¡æ•°</th>
</tr>
</thead>
<tbody>
<tr>
<td>RNA-seq</td>
<td>5</td>
</tr>
<tr>
<td>carcinoma</td>
<td>4</td>
</tr>
<tr>
<td>immune</td>
<td>3</td>
</tr>
<tr>
<td>single-cell</td>
<td>3</td>
</tr>
<tr>
<td>resistance</td>
<td>2</td>
</tr>
<tr>
<td>genome</td>
<td>2</td>
</tr>
<tr>
<td>tumor</td>
<td>1</td>
</tr>
<tr>
<td>tumor microenvironment</td>
<td>1</td>
</tr>
<tr>
<td>antibody</td>
<td>1</td>
</tr>
<tr>
<td>ChIP-seq</td>
<td>1</td>
</tr>
<tr>
<td>metabolic</td>
<td>1</td>
</tr>
<tr>
<td>Alzheimer</td>
<td>1</td>
</tr>
<tr>
<td>spatial</td>
<td>1</td>
</tr>
<tr>
<td>spatial transcriptomics</td>
<td>1</td>
</tr>
<tr>
<td>transcriptomics</td>
<td>1</td>
</tr>
<tr>
<td>pathway</td>
<td>1</td>
</tr>
</tbody>
</table>
<hr />
<h2>ğŸ“ æ›´å¤šå†…å®¹</h2>
<details>
<summary><a name="æ›´å¤š-æ•°æ®å‰æ²¿"></a>ğŸ§¬ æ•°æ®å‰æ²¿ å…¶ä»–å†…å®¹ (7æ¡)</summary>
<div class="details-content">
<ul>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE314682" target="_blank" rel="noopener noreferrer">GSE314682 æŸ“è‰²è´¨ç»„è£…å› å­ 1 æ˜¯ç²—ç³™è„‰å­¢èŒæ­£å¸¸åŸºå› æŠ‘åˆ¶å’Œå…¼æ€§å¼‚æŸ“è‰²è´¨å½¢æˆæ‰€å¿…éœ€çš„ [RNA-seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE313930" target="_blank" rel="noopener noreferrer">GSE313930 å°é¼ ä¸»åŠ¨è„‰å¹³æ»‘è‚Œç»†èƒä¸­Ano1ç¼ºé™·å¼•èµ·çš„æŸ“è‰²è´¨çŠ¶æ€å˜åŒ–çš„å…¨åŸºå› ç»„å›¾è°±</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE294848" target="_blank" rel="noopener noreferrer">GSE294848 ç¿»è¯‘ä¿ç•™çš„ç¬¬11å·å†…å«å­åºåˆ—èµ‹äºˆé˜¿å°”èŒ¨æµ·é»˜ç—…ä¸­Tauè›‹ç™½ç—…ç†ç‰¹æ€§</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE284309" target="_blank" rel="noopener noreferrer">GSE284309 cMaf æ”¯æŒ Zeb2 åœ¨åŸå§‹é€ è¡€ä¸­çš„è¡¨è¾¾ï¼ˆFL å• RNA-seqï¼‰</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE283975" target="_blank" rel="noopener noreferrer">GSE283975 cMaf æ”¯æŒ Zeb2 åœ¨åŸå§‹é€ è¡€ä¸­çš„è¡¨è¾¾ï¼ˆTRM RNA-seqï¼‰</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE254169" target="_blank" rel="noopener noreferrer">GSE254169 é«˜è´¨é‡çš„çŸ³æ–›æŸ“è‰²ä½“æ°´å¹³å‚è€ƒåŸºå› ç»„ä¸ºè‹¦å‘³ç´ å‹å€åŠèœç”Ÿç‰©ç¢±çš„ç”Ÿç‰©åˆæˆå’Œç§¯ç´¯æä¾›äº†æ–°çš„è§è§£</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE251891" target="_blank" rel="noopener noreferrer">GSE251891 AUF1 é€šè¿‡è°ƒæ§å¬è§‰æ¯›ç»†èƒä¸­å…ç–«ååº”åŸºå› çš„è½¬å½•å’Œé€‰æ‹©æ€§å‰ªæ¥æ¥è°ƒèŠ‚è¡°è€</a></li>
</ul>
</div>
</details>

<hr />
<p><em>ğŸ“… æŠ¥å‘Šç”Ÿæˆæ—¶é—´ï¼š2025-12-26 21:36</em><br />
<em>ğŸ¤– ç”± GitHub Actions è‡ªåŠ¨ç”Ÿæˆ</em></p>
    </div>
</body>
</html>